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Purpose: To evaluate the therapeutic effect of adipose-derived regenerative cell (ADRC) 6 
administration on tendon-bone healing in a rabbit ACL reconstruction model. 7 
Methods: Anterior cruciate ligament (ACL) reconstruction with semitendinosus tendon autograft 8 
was performed on the right knees of adult white rabbits. Eighty rabbits were divided into 2 groups: 9 
a treatment group, in which the graft was coated with ADRCs mixed in fibrin glue carrier during 10 
surgery, and a control group, in which the graft was coated with fibrin glue only. At 2, 4, 6, 8, and 12 11 
weeks postoperatively, 8 rabbits were sacrificed in each group. Three were used for histological 12 
evaluation at the tendon-bone interface, and 5 for biomechanical examination. 13 
Results: In histological analysis, chondroid cells appeared more orderly and more regular in size 14 
and shape, and Sharpey-like fibers, which connected the tendon graft and bone tissue, appeared 15 
earlier in ADRC-treated tissues than in control tissues. In biomechanical analysis, the ultimate 16 
failure load in the ADRC-treated group was significantly greater than that in the control group at 2 17 
and 4 weeks (29.5 ± 7.2 N vs. 20.9 ± 2.7 N; P = .016 and 32.3 ± 3.9 N vs 22.8 ± 5.4 N; P = .016, 18 
respectively). Stiffness was significantly higher in the ADRC-treated group than in the control 19 
group at 6 weeks (21.7 ± 5.9 N/mm vs. 12.6 ± 4.9 N/mm; P = .037). Although the ultimate failure 20 
load and stiffness of the ADRC-treated limb was higher than that of the limb in the control group at 21 
8 and 12 weeks, these differences were not significant. 22 
Conclusions: Local administration of ADRCs promoted the early healing process at the tendon-bone 23 
junction, both histologically and mechanically, in the rabbit ACL reconstruction model. 24 





Autologous tendon grafts are currently popular for anterior cruciate ligament (ACL) reconstruction. 29 
Secure healing between tendon and bone is necessary for successful ACL reconstruction. However, 30 
tendon-bone healing occurs slowly, which can limit early return to sports activities. Several studies 31 
have shown that tendon-bone healing occurs more slowly than bone-to-bone healing,1-3 which raises 32 
concerns regarding the adhesive strength between tendon graft and bone tunnels and the 33 
subsequent risk of graft failure. Interventions that can improve and accelerate tendon-bone healing 34 
could potentially reduce the rate of graft failure and allow for early aggressive rehabilitation. 35 
 36 
Adipose tissue has been gaining attention as a promising source of undifferentiated mesenchymal 37 
stem cells. Adipose-derived regenerative cells (ADRCs) have multilineage potential equivalent to 38 
bone marrow-derived stem cells and can be easily obtained in large amounts from subcutaneous 39 
adipose tissue without the need for culture and expansion.4,5 Although a number of reports have 40 
been published regarding clinical applications of ADRCs,6-16 we are unaware of any study 41 
investigating ADRCs for their potential benefit in enhancing tendon graft healing in a bone tunnel. 42 
The aim of this study was to evaluate the therapeutic effect of ADRC administration on 43 
tendon-bone healing in a rabbit ACL reconstruction model. We hypothesized that ADRC 44 
administration at the tendon-bone interface may promote the healing between tendon graft and 45 
bone tunnel. 46 




Experimental Design 50 
Eighty-two female Japanese white rabbits (age, 15-17 weeks) weighing between 3.0 and 3.5 kg were 51 
used in this study. Because of the unified standards, we integrated the sex of the animals. We did 52 
not especially mean anything by selecting female rabbits. ACL reconstruction with a 53 
semitendinosus tendon autograft was performed on the right knee. Eighty animals were randomly 54 
divided into 2 groups, and the remaining 2 were used for tracing of ADRCs. In the treatment group, 55 
the graft was coated with ADRCs mixed in fibrin glue carrier during surgery. In the control group, 56 
the graft was coated with fibrin glue only. The animals in both groups were divided into five 57 
subgroups and killed at 2, 4, 6, 8, and 12 weeks postoperatively; thus, 8 animals per group were 58 
sacrificed at each time point after surgery, at which time femur-graft-tibia complexes were 59 
harvested for histological and biomechanical evaluations. In all subgroups, 5 of the 8 rabbits were 60 
used for biomechanical evaluation, and the remaining 3 were used for histological observation. The 61 
animal experiments were conducted with the approval of the Institutional Animal Care and Use 62 
Committee and carried out in strict accordance with its regulations. 63 
 64 
ADRC Preparation 65 
ADRCs were isolated by modifying a previously established method.17,18 Adipose tissue (1.5 g) of 66 
female rabbits that were not included in the study was harvested from the adipose tissue pouch on 67 
the interscapular region located along the dorsomedial line, nearly 5 cm from the skull in the 68 
craniocaudal direction, and then washed with phosphate-buffered saline (PBS, Wako, Osaka, 69 
Japan). The tissue was cut into strips over a period of 5 min. Collagenase (Wako) was dissolved in 70 
PBS for a concentration of 0.12% in 20 ml and used to digest adipose tissue at 37°C for 45 min in a 71 
water bath. The mixture was shaken every 15 min during the digestion period. Immediately after 72 
the reaction was completed, 20 mL of Dulbecco’s modified Eagle’s medium (DMEM, Wako) was 73 
added, and collagenase activity was neutralized. The resulting solution was filtered. The filtrate 74 
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was centrifuged at 1300 rpm for 6 min at 25°C, and the supernatant was removed. The pellet of 75 
ADRCs was subsequently administered at the tendon-bone junction. Approximately 1 × 105 cells 76 
were included in this pellet. 77 
 78 
Surgical Procedure 79 
Surgery was performed in accordance with the Guide for the Care and Use of Laboratory Animals 80 
published by the US National Institutes of Health (NIH publication no. 85-23, revised 1996). The 81 
animals were operated on under general anesthesia with subcutaneous injection of xylazine (5 82 
mg/kg body weight; Bayer, Tokyo, Japan), and sedation was maintained by intravenous injection of 83 
2.5% sodium phenobarbital (Kyoritsu Pharmaceutical, Tokyo, Japan). Using an aseptic technique, 84 
we approached the right knee joint through a medial parapatellar incision. The semitendinosus 85 
tendon was identified and transected at its musculotendinous junction, and the graft was prepared 86 
by removing the attached muscle and passing the holding sutures through each end of the tendon 87 
graft. The original ACL was resected, and then tunnels (2.0 mm in diameter) were drilled in the 88 
lateral femoral condyle and the medial aspect of the tibia at the footprint of the original ACL. The 89 
graft was routed through the tunnels, and then the previously mentioned materials were injected 90 
onto the interface between the grafted tendon and the bone tunnel. In the ADRC group, 0.2 ml of 91 
fibrin glue containing ADRCs was injected. On the other hand, in the control group, an equal 92 
amount of fibrin glue only was injected onto the interface. In the 2 animals used for tracing of 93 
ADRCs, the equal amount of fibrin glue containing ADRCs labeled with 94 
1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine perchlorate (DiI) was injected. After the 95 
injection, both graft ends were secured under tension to the neighboring soft tissue with 2-0 96 
Ethibond suture (Ethicon, Somerville, New Jersey). The incision was closed at each layer in a 97 
standard fashion. Postoperatively, the limbs were not immobilized, and the animals were allowed 98 
normal activity in individual cages. At each time point after surgery, the animals were sacrificed 99 
with an overdose of intravenous pentobarbital after general anesthesia. 100 
 101 
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Histological Evaluation 102 
At the time the animals were killed, the entire joint including the femoral and tibial bone tunnels 103 
was harvested. For histological observation, tissues were fixed in 10% formalin, and conventional 104 
paraffin-embedded sections were prepared. The samples were cut into 5-μm-thick sections 105 
longitudinal to the bone tunnels in the femur and tibia and stained with hematoxylin and eosin 106 
(H&E) for the examination of healing at the interface between the tendon graft and bone tunnel 107 
under light microscopy. Bone-tendon healing was graded in a semiquantitative manner with a scale 108 
from 0 (worst) to 8 (best) using a modified version of the histological scoring system of Nakase et 109 
al.19 based on new tissue formation at the interface and graft remodeling (Table 1). The two sections 110 
of each specimen were graded by two investigators (J.N., K.H.) in a blinded fashion, and the mean 111 
histologic scores of the two observers were determined as the final results to minimize sampling 112 
error and misinterpretation. 113 
 114 
ADRC Labeling 115 
In the 2 animals used for tracing of ADRCs, cells were labeled with DiI (Vybrant® DiI Cell Labeling 116 
Solution; Life Technologies, Carlsbad, CA, USA) and transplanted to confirm the survival potential 117 
and location of transplanted ADRCs. DiI binds to cellular thiols and has long-term stability, which 118 
enables the tracing of DiI-labeled transplanted cells in the host tissue. Two weeks after injection of 119 
labeled cells, the rabbits were euthanized, and frozen sections were prepared in the longitudinal 120 
plane. The presence of Dil-labeled cells in the bone tunnel was then observed using a fluorescence 121 
microscope. 122 
 123 
Biomechanical Evaluation 124 
At the time of each animal’s death, the femur and tibia were sectioned 5 cm from the knee joint. In 125 
addition, 5 knees of normal rabbits were evaluated to obtain the structural biomechanical 126 
properties with intact ACLs. All soft tissues around the knee were carefully removed except for the 127 
tendon graft connecting the 2 bones. The suture material used to secure the grafts during surgery 128 
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was also disturbed. Each specimen was stored at -80°C until testing. Before mechanical testing, 129 
each knee was thawed overnight at 4°C. The femur and tibia were separately mounted in 130 
cylindrical aluminum tubes using polymethylmethacrylate resin. During all preparations and 131 
testing, specimens were kept moist with saline spray. These samples were mounted on an 132 
electromechanical testing machine (Legacy 4482, Instron, Kanagawa, Japan), and all mechanical 133 
testing was conducted by one investigator (M.K.). Each femur-graft-tibia complex was mounted in a 134 
custom jig to ensure that the tensile load could be applied along the longitudinal axis of both the 135 
femoral and tibial tunnels. The femur-graft-tibia complex was applied with a preload of 1 N for 30 136 
seconds, and the specimen was cycled 5 times between elongation limits of 0 and 0.75 mm at a rate 137 
of 2 mm/min. A tensile force was applied at a constant elongation rate of 20 mm/min. The ultimate 138 
load at the point of failure was recorded. The stiffness was calculated from the slope of the linear 139 
region of the load-displacement curve. Furthermore, the site of failure, either by pullout of the 140 
tunnel or midsubstance graft rupture, was determined by gross examination. 141 
 142 
Statistical Analysis 143 
The semiquantitative histological scores, mean ultimate failure load, and stiffness between 144 
treatment and control groups were compared using the Mann-Whitney U test. The inter-observer 145 
reliability was assessed by kappa () statistic, and agreement in percentage was calculated. The 146 
Mann-Whitney U test was also used for the comparison of biomechanical properties at different 147 
time points within each group. The failure patterns of the femur-graft-tibia complex shown by the 148 
biomechanical testing were analyzed with the Fisher exact test. Differences were considered 149 
statistically significant at P < .05. 150 
  151 
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Results  152 
 153 
In this study, except minor redness and swelling at the reconstructed knee, there were no 154 
premature deaths, nor were there any serious joint infections on postmortem examination of the 155 
knees. All of the animals were euthanized at the planned times. 156 
 157 
Histological Analysis 158 
The adhesion of tendon to bone was analyzed histologically during the 12 weeks after treatment. At 159 
2 weeks after surgery, in the control group, light microscopic examination revealed inflammatory 160 
response around the autografts and a highly cellular, vascular, and fibrous tissue infiltrating the 161 
interface (Fig 1A). Poorly organized and sparse collagen fibers appeared at the interface of the bone 162 
and the tendon graft. At 2 weeks in the ADRC-treated group, fibrovascular tissue appeared better 163 
organized, and cartilaginous tissue had appeared (Fig 1B). At 4 weeks, loose connective tissue 164 
characterized by directionally arranged collagen fibers was seen in fibrovascular tissue, and large 165 
areas of fairly disorganized cartilaginous tissue were observed around the tendon-bone interface in 166 
the control group (Fig 1C). In the ADRC-treated group, the fibrovascular interface tissue became 167 
denser and better organized, and occasionally Sharpey-like fibers, which connected the tendon graft 168 
and bone tissue, appeared. In addition, the chondroid cells appeared more regular in size and shape, 169 
with more orderly laying down of chondro-osteoid matrix (Fig 1D). At 6 weeks, the area between 170 
tendon and bone was seen to become more mature, with the fibrous connective tissue and 171 
narrowing of the distance between the tendon and bone in both groups (Fig 1E,F). The chondroid 172 
cells were closely associated with surrounding tendon and bone, and fibrocartilaginous tissue was 173 
seen to gradually blend into the tendon substance especially in the ADRC-treated group (Fig 1F). At 174 
8 weeks, the interface area between tendon and bone was still a distinct entity, although it was 175 
definitely narrower in both groups (Fig 1G,H). The interface was more organized and mature in the 176 
ADRC-treated group (Fig 1H). At 12 weeks, gradual blending of fibrocartilaginous tissue into the 177 
tendon substance and occasionally mineralized fibrocartilaginous tissue appeared in the control 178 
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group (Fig 1I). In the ADRC-treated group, a gradual and smooth transition was seen from bone to 179 
mineralized fibrocartilaginous tissue, fibrocartilaginous tissue, and finally tendon (Fig 1J). 180 
Bone-tendon healing was graded in a previously described manner, and the score of both groups 181 
increased with time. For example, in one case histological appearance was scored 2 (1 based on graft 182 
remodeling and 1 based on new tissue formation at the interface) at 2 weeks (Fig 1A), and scored 6 183 
(2 based on graft remodeling and 4 based on new tissue formation at the interface) at 8 weeks (Fig 184 
1G). The semiquantitative score of tendon-bone healing quality was significantly higher in the 185 
ADRC-treated group than in the control group at 2, 4, and 6 weeks postoperatively (all P < .05) 186 
(Table 2). The percentage of agreement and  for inter-observer reliability were 78.3 and 0.737, 187 
respectively. 188 
 189 
ADRC Labeling 190 
The distribution of DiI-positive (red) areas was detected at 2 weeks after transplantation (Fig. 2). 191 
DiI labeling suggested that the transplanted cells had survived and were localized to the site where 192 
they were transplanted at 2 weeks post-transplantation. The transplanted cells survived up to at 193 
least 2 weeks after transplantation, with some cells being focally distributed in the bone tunnel. 194 
 195 
Biomechanical Analysis 196 
Fifty limbs were analyzed after ACL reconstruction. The ultimate failure load of the 2 groups 197 
increased with time. The ADRC-treated limb generally had a greater failure load than the limb in 198 
the control group. There were significant increases between the ADRC-treated group and the 199 
control group at 2 weeks (29.5 ± 7.2 N and 20.9 ± 2.7 N, respectively; P = .016) and 4 weeks (32.3 ± 200 
3.9 N and 22.8 ± 5.4 N, respectively; P = .016). Although the ultimate failure load of the 201 
ADRC-treated limb was higher than that of the limb in the control group at 6 weeks (34.2 ± 5.3 N 202 
and 26.6 ± 5.9 N, respectively; P = .076), 8 weeks (43.7 ± 17.5 N and 36.5 ± 15.1 N, respectively; P 203 
= .076), and 12 weeks (61.0 ± 18.5 N and 57.2 ± 12.5 N, respectively; P = .754), the difference was 204 
 10 
not significant (Fig 3). The within-group analysis showed significant differences between 2 weeks 205 
and 12 weeks, 4 weeks and 12 weeks, and 6 weeks and 12 weeks in the ADRC-treated group, and 206 
between 2 weeks and 8 weeks, 2 weeks and 12 weeks, 4 weeks and 8 weeks, 4 weeks and 12 weeks, 207 
6 weeks and 12 weeks, and 8 weeks and 12 weeks in the control group (P = .016, P = .016, P = .016, 208 
P = .009, P = .009, P = .016, P = .009, P = .009 and P = .047, respectively). The ultimate failure loads 209 
of the limbs in both ACL reconstructed groups were much weaker than those of intact ACLs (273.1 210 
± 27.3 N) (P < .001). 211 
 212 
The stiffness in the ADRC-treated group was significantly higher than that in the control group at 6 213 
weeks (21.7 ± 5.9 N/mm and 12.6 ± 4.9 N/mm, respectively; P = .037). There were no significant 214 
differences in stiffness between the groups at 2 weeks (15.4 ± 8.1 N/mm and 11.5 ± 2.9 N/mm, 215 
respectively; P = .465), 4 weeks (17.2 ± 8.0 N/mm and 13.9 ± 5.6 N/mm, respectively; P = .917), 8 216 
weeks (23.3 ± 13.6 N/mm and 17.3 ± 12.3 N/mm, respectively; P = .076), and 12 weeks (30.2 ± 12.7 217 
N/mm and 26.8 ± 11.1 N/mm, respectively; P = .917) (Fig 4). The within-group analysis showed 218 
significant differences between 2 weeks and 12 weeks in the ADRC-treated group, and between 2 219 
weeks and 8 weeks, 2 weeks and 12 weeks, and 6 weeks and 12 weeks in the control group (P = .047, 220 
P = .046, P = .047 and P = .047, respectively). 221 
 222 
At 2 and 4 weeks, all tendons were pulled away from the bone tunnel at the failure point. At 6 223 
weeks, 1 of the 5 ADRC-treated limbs failed by rupture in the midsubstance of the tendon, while all 224 
of the control limbs failed by tendon pullout from the bone tunnel. At 8 weeks, 1 each of the 5 225 
ADRC-treated limbs and control limbs failed by rupture in the midsubstance. At 12 weeks, 3 of 5 226 
ADRC-treated limbs and 2 of 5 control limbs failed by rupture in the midsubstance. Fisher exact 227 
test showed no significant difference between the rates of pullout in the ADRC-treated and control 228 
limbs in each time point and overall. 229 




This study demonstrated that local administration of ADRCs has the potential to promote healing 233 
at the tendon-bone interface, both histologically and mechanically, in a rabbit model of ACL 234 
reconstruction. Histological maturation occurred earlier, and the semiquantitative score of 235 
tendon-bone healing quality at 2, 4, and 6 weeks postoperatively was significantly higher in 236 
ADRC-treated tissues than in control tissues. Biomechanical properties were significantly better in 237 
the ADRC-treated group than the control group at 2 and 4 weeks after surgery in terms of the 238 
ultimate failure load. 239 
 240 
Several investigators have demonstrated positive effects of stem cells on tendon-bone healing. Lim 241 
et al.20 reported that coating of tendon grafts with mesenchymal stem cells (MSCs) in ACL 242 
reconstruction promoted healing by the formation of an intervening zone of cartilage resembling the 243 
chondral enthesis of the normal ACL insertion. They also found that MSC-enhanced 244 
reconstructions demonstrated significantly higher failure load and stiffness than controls on 245 
biomechanical tests in rabbits. Similarly, Soon et al.21 reported that MSCs applied at the 246 
tendon-bone interface during ACL reconstruction resulted in the development of an intervening 247 
zone of fibrocartilage and improvement in load-to-failure rates. Li et al.22 reported that bone 248 
marrow mesenchymal stem cell (BMSC) transplantation to the tendon-bone interface was shown to 249 
enhance its mechanical properties by promoting tendon-bone tunnel healing at early time points 250 
4–8 weeks after ACL reconstruction. Mifune et al.23 reported that ACL-derived stem cells 251 
contributed to the tendon-bone healing after ACL reconstruction by enhancing angiogenesis and 252 
osteogenesis, which in turn contributed to increasing biomechanical strength. Lui et al.24 reported 253 
that wrapping the ACL graft with a sheet of tendon-derived stem cells before graft insertion 254 
promoted graft healing in the early stage after ACL reconstruction radiographically, histologically, 255 
and biomechanically in a rat model. 256 
 257 
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These studies suggest that many types of stem cells can improve the tendon-bone healing process 258 
and result in better mechanical properties. However, these agents also have drawbacks to clinical 259 
use because of concerns such as donor site morbidity, limitation of the cell source, difficulty of 260 
isolating stem cells, time and effort required for ex vivo culture of stem cells and formation of a cell 261 
sheet if needed, possible side effects after transplantation in humans, and ethical considerations. 262 
 263 
The stromal vascular fraction of adipose tissue contains a mixed, multipotent population of cells, 264 
and a number of investigations have described the potential applications of adipose-derived stem 265 
cells (ADSCs).4,5,17,18,25 ADRCs are the nonbuoyant cellular fraction containing several types of stem 266 
and regenerative cells, including ADSCs, vessel-forming cells such as endothelial and smooth 267 
muscle cells and their progenitors, and preadipocytes.26 ADSCs and ADRCs could be used in 268 
regenerative medicine in various conditions.6-16 According to an in vitro study, ADSCs, similar to 269 
BMSCs, can differentiate into various cell types, including adipocytes, chondroblasts, endothelial 270 
cells, fibroblasts, myoblasts, and osteoblasts.4,5,17,25,27 On the basis of both in vitro experiments and 271 
preclinical studies, multiple reports have already been published regarding clinical applications of 272 
ADSCs and ADRCs, including beneficial results of their use in breast reconstruction.6,7 There are 273 
also reports of their use to treat ischemic cardiomyopathy,8 calvarial bone defects,9 enterocutaneous 274 
fistulas in patients with Crohn’s disease,10 and chronic ulcers caused by radiotherapy.11 Recently, 275 
various basic and applied studies on the use of ADSCs in the orthopaedic field also have been 276 
conducted.12-16 In addition, ADSCs have immunosuppressive properties that can be used to control 277 
graft-versus-host disease.28 278 
 279 
ADRCs have several advantages as a source of tissue stem cells that led us to focus on them in this 280 
study. First, autologous ADRCs can be easily isolated in large amounts from abundant and 281 
accessible subcutaneous adipose tissue. Furthermore, harvesting of ADRCs is less invasive than 282 
that of BMSCs and other stem cells, and many more stem cells can be harvested at one time.29 283 
Adipose tissue yields approximately 500-fold more stem cells than the same amount of adult bone 284 
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marrow.4,27 In addition, as mentioned above, ADRCs have already been applied in various clinical 285 
fields. For the above reasons, we have considered ADRCs a potentially efficient source for clinical 286 
applications in promoting tendon-bone healing. 287 
 288 
ADSCs have the ability not only to directly differentiate into some types of topical cells but also to 289 
indirectly facilitate the healing process by promoting the secretion of various humoral factors also 290 
called paracrine effects.30,31 In secretory protein analysis, ADSCs secrete significantly larger 291 
amounts of growth factors and inflammatory cytokines, such as vascular endothelial growth factor, 292 
hepatocyte growth factor, and interleukin 6, than BMSCs.30 ADRCs contain ADSCs, vessel-forming 293 
cells such as endothelial and smooth muscle cells and progenitors, and preadipocytes.26  294 
 295 
Limitations 296 
There are several limitations to this study. First, we chose to use a rabbit model of ACL 297 
reconstruction. This model has been validated in previous reports in the literature.3,20 However, 298 
studies using small-animal models of ACL reconstruction have inherent problems such as a wide 299 
range in biomechanical results, which was also seen in the present study.20 In addition, the healing 300 
potential of small animals is different from that of humans. Therefore, the results obtained from 301 
this animal model cannot be assumed to be directly applicable to clinical settings. More accurate 302 
and reliable results may have been achieved with the use of a larger animal model. Second, we did 303 
not conduct a histological analysis of the intra-articular portion of the graft. Although this 304 
evaluation was not included as an aim of this study, remodeling of the graft midsubstance is also an 305 
important part of graft healing and could affect the results of biomechanical analysis. The failure 306 
patterns of the femur-graft-tibia complex shown by biomechanical testing changed from pullout 307 
from the bone tunnel to rupture in the midsubstance with time. This shift could be the result of 308 
changes in the histological features of the intra-articular graft. Third, the sample size in each group 309 
was relatively small, while we studied multiple time points and thus had information on changes 310 
over time. Although the blinded nature of this study avoids biases in the assessments, the small 311 
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sample size limits the statistical rigor of the findings and efficacy conclusions of the study. Future 312 
investigations with a larger sample size at specific time periods would increase the strength of this 313 
study for a more accurate evaluation of the effects of ADRCs on tendon-bone healing. Fourth, we did 314 
not identify the proper cell concentration in the pellet and its true contents. We calculated the 315 
number of cells in the pellet using a microscope, and our result was similar to the concentration 316 
assumed from previous studies. Additionally, ADRCs are known to contain ADSCs and several 317 
other types of cells and their progenitors, as mentioned above. However, for a stricter analysis, a 318 
rigorous analysis of the pellet is necessary using indirect methods, such as flow cytometry and 319 
indirect immunofluorescence of the pellet. In addition, we did not trace labeled ADRCs over a 320 
longer period, although we confirmed that the cells implanted with the fibrin glue infiltrated into 321 
the bone-tendon interface at 2 weeks after ACL reconstruction. We are thus unable to comment on 322 
whether the healing tissue at the tendon-bone junction originated from the ADRCs themselves or 323 
from cells recruited locally. Analysis of the fate of the ADRCs is the subject of a subsequent study by 324 
our group. Fifth, we did not have a group without fibrin glue. Shoemaker et al.32 had previously 325 
examined the effects of fibrin glue on the healing of tendons to bone tunnels in the proximal tibia in 326 
dogs. In the first 2 weeks after surgery, fibrin glue appeared to speed up the organization of the 327 
fibrovascular interface, but no histological differences were visible between the two groups with or 328 
without fibrin glue at 28 days. Although biomechanical evaluation was not performed in that 329 
experiment, we believe that using a fibrin glue carrier in both the treatment and control 330 
reconstructions did not appreciably influence the outcome of our results. Sixth, the histological 331 
findings presented in this study were mainly subjective and preliminary. More objective and precise 332 
quantitative methods are needed for more accurate evaluations. Molecular biological data or 333 
immunohistological examination may also be valuable for showing the underlying mechanisms by 334 
which ADRCs aid ACL reconstruction. 335 
 336 
Conclusions 337 
Local administration of ADRCs promoted the early healing process at the tendon-bone junction, 338 
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both histologically and mechanically, in the rabbit ACL reconstruction model. 339 
  340 
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Figure Legends 424 
 425 
Fig 1. The healing process between tendon graft and bone tissue after anterior cruciate ligament 426 
reconstruction. Representative photomicrographs from the control limbs (upper row: A-E) and the 427 
adipose-derived regenerative cell (ADRC)-treated limbs (lower row: F-J) at 2, 4, 6, 8, and 12 weeks 428 
after surgery (hematoxylin and eosin, original magnification ×100). The histological maturation at 429 
the tendon-bone interface occurred earlier and was more improved in the ADRC-treated tissues 430 
than that in the control tissues, especially in the early period after surgery. (B, bone; IF, interface; T, 431 
tendon graft.) 432 
 433 
Fig 2. Serial sections of an adipose-derived regenerative cell-treated limb showing (A) histology of 434 
the tendon-bone interface at 2 weeks after surgery stained with hematoxylin and eosin (original 435 
magnification ×40) and (B) fluorescence microscopy for DiI. Dil-labeled cells at the tendon-bone 436 
interface were observed under a fluorescent microscope using frozen tissue sections. Red 437 
fluorescence indicating Dil-labeled cells was clearly visible on the tendon-bone interface at 2 weeks 438 
after surgery (original magnification ×40). (B, bone; IF, interface; T, tendon graft) 439 
 440 
Fig 3. Biomechanical properties of the femur-graft-tibia complex after anterior cruciate ligament 441 
(ACL) reconstruction. Bar charts showing the ultimate load at the point of failure of the 442 
femur-graft-tibia complex at each time frame after ACL reconstruction in the control and 443 
adipose-derived regenerative cell (ADRC)-treated groups (*P < .05). The ultimate failure load in the 444 
ADRC-treated group was significantly greater than that in the control group at 2 and 4 weeks after 445 
surgery (P = .016 and P = .016, respectively). 446 
 447 
Fig 4. Bar charts showing the stiffness of the femur-graft-tibia complex at each time frame after 448 
anterior cruciate ligament reconstruction in the control and adipose-derived regenerative cell 449 
(ADRC)-treated groups (*P < .05). The stiffness in the ADRC-treated group was significantly higher 450 
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than that in the control group at 6 weeks after surgery (P = .037). 451 
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Table 1. Scoring System for Histological Examination 453 
Histological features Points 
Graft remodeling  
None (0% of graft) 0 
Slight (<10% of graft) 1 
Fair (<25% of graft) 2 
Moderate (<50% of graft) 3 
Abundant (≥50% of graft) 4 
Interface connection / integration  
 None 0 
 No directivity of collagen fiber 1 
 Appearance of directivity of collagen fiber 2 
 Appearance of fibrocartilaginous tissue 3 
 Appearance of mineralized cartilaginous tissue 4 
NOTE. The maximum possible score is 8 points. 454 
  455 
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Table 2. Histological Scoring and Comparison between Groups 456 
Time Point ADRC-treated Control P value 
2 wk 3.8 ± 0.7 2.3 ± 0.4 .005 
4 wk 4.7 ± 0.4 3.1 ± 0.6 .005 
6 wk 5.8 ± 0.4 3.6 ± 0.8 .005 
8 wk 6.5 ± 0.5 5.8 ± 0.8 .093 
12 wk 6.9 ± 0.7 6.3 ± 0.5 .149 
NOTE. Data are given as mean ± standard deviation. 457 
 458 
